|
EQS-Ad-hoc: aap Implantate AG / Key word(s): Capital Increase The Management Board of aap Implantate AG ("Company") today resolved, with the approval of the Supervisory Board, to increase the Company's share capital from currently EUR 10,979,625.00 by EUR 1,097,962.00 to EUR 12,077,587.00 by issuing 1,097.962 new no-par value bearer shares, each with a pro rata amount of the share capital of EUR 1.00 ("New Shares"), against cash contributions, making partial use of the authorized capital 2024/I and excluding shareholders' subscription rights ("Cash Capital Increase"). The issue price per New Share is EUR 2.03. The Cash Capital Increase corresponds to around 10% of the existing share capital. The New Shares will be issued by way of a private placement to selected investors. The New Shares will carry dividend rights from January 1, 2024. The cash capital increase serves to provide the necessary liquidity and strengthen the company's equity base, thus securing its financing in the medium term, assuming normal business development. The gross issue proceeds from the cash capital increase will amount to around EUR 2.2 million. In order to further strengthen the equity base, the Management Board of the company also intends, with the approval of the Supervisory Board, to increase the company's share capital by up to EUR 400,000.00 (approx. 3.6% of the current share capital) against contributions in kind, excluding shareholders' subscription rights, making further partial use of the authorized capital 2024/I. The object of the contribution in kind is to be shareholder loans granted to the company in the nominal amount of EUR 750,000.00 plus accrued interest, which are to be contributed to the company by way of a debt-to-equity swap in return for the granting of up to 400,000 new shares. The issue price of the New Shares therefore also corresponds to EUR 2.03. The implementation of the capital increase against contributions in kind requires a non-cash contribution audit by a court-appointed non-cash contribution auditor. The capital increase against contributions in kind serves to strengthen the balance sheet structure by increasing equity while at the same time eliminating loan obligations and leads to a reduction in the interest burden associated with the granting of shareholder loans.
Contact: If you have any questions, please contact: aap Implantate AG; R. Di Girolamo; Chairman of the Management Board/CEO; Lorenzweg 5; D-12099 Berlin Tel.: +49/30/750 19 – 170; Fax: +49/30/750 19 – 290; r.digirolamo@aap.de
End of Inside Information
22-Oct-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | aap Implantate AG |
| Lorenzweg 5 | |
| 12099 Berlin | |
| Germany | |
| Phone: | +49 (0) 30 75 019-0 |
| Fax: | +49 (0) 30 75 019-111 |
| E-mail: | info@aap.de |
| Internet: | www.aap.de |
| ISIN: | DE000A3H2101 |
| WKN: | A3H210 |
| Listed: | Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2013719 |
| End of Announcement | EQS News Service |
|
|
2013719 22-Oct-2024 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
